The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats.

Allen ME, Pennington ER, Perry JB, Dadoo S, Makrecka-Kuka M, Dambrova M, Moukdar F, Patel HD, Han X, Kidd GK, Benson EK, Raisch TB, Poelzing S, Brown DA, Shaikh SR

Communications biology17 Jul 2020Cited by 84 (Europe PMC)

PMID32680996PMCIDPMC7368046DOI10.1038/s42003-020-1101-3PepBankPUB-32680996

Download PDF PubMedAsk about this study

Jump to 6 results

Summary

Mitochondrial dysfunction contributes to cardiac pathologies. Barriers to new therapies include an incomplete understanding of underlying molecular culprits and a lack of effective mitochondria-targeted medicines. Here, we test the hypothesis that the cardiolipin-binding peptide elamipretide, a clinical-stage compound under investigation for diseases of mitochondrial dysfunction, mitigates impairments in mitochondrial structure-function observed after rat cardiac ischemia-reperfusion. Respirometry with permeabilized ventricular fibers indicates that ischemia-reperfusion induced decrements in the activity of complexes I, II, and IV are alleviated with elamipretide. Serial block face scanning electron microscopy used to create 3D reconstructions of cristae ultrastructure reveals that disease-induced fragmentation of cristae networks are improved with elamipretide. Mass spectrometry shows elamipretide did not protect against the reduction of cardiolipin concentration after ischemia-reperfusion. Finally, elamipretide improves biophysical properties of biomimetic membranes by aggregating cardiolipin. The data suggest mitochondrial structure-function are interdependent and demonstrate elamipretide targets mitochondrial membranes to sustain cristae networks and improve bioenergetic function.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rat hearts after ischemia-reperfusion, elamipretide alleviated the decrement in complex I activity.
In plain wordsIn rats, elamipretide eased the drop in mitochondrial complex I activity in heart fibers after ischemia-reperfusion.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseComplex I activity after ischemia-reperfusion
Study
ratn: not reported in source
permeabilized ventricular fibers
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Respirometry with permeabilized ventricular fibers indicates that ischemia-reperfusion induced decrements in the activity of complexes I, II, and IV are alleviated with elamipretide.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we test the hypothesis that the cardiolipin-binding peptide elamipretide, a clinical-stage compound under investigation for diseases of mitochondrial dysfunction, mitigates impairments in mitochondrial structure-function observed after rat cardiac ischemia-reperfusion.
Show in the study text Report a problemFND-3268099601
02AnimalAnimal study (in vivo)Efficacy outcome
In rat hearts after ischemia-reperfusion, elamipretide alleviated the decrement in complex II activity.
In plain wordsIn rats, elamipretide eased the drop in mitochondrial complex II activity in heart fibers after ischemia-reperfusion.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseComplex II activity after ischemia-reperfusion
Study
ratn: not reported in source
permeabilized ventricular fibers
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Respirometry with permeabilized ventricular fibers indicates that ischemia-reperfusion induced decrements in the activity of complexes I, II, and IV are alleviated with elamipretide.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we test the hypothesis that the cardiolipin-binding peptide elamipretide, a clinical-stage compound under investigation for diseases of mitochondrial dysfunction, mitigates impairments in mitochondrial structure-function observed after rat cardiac ischemia-reperfusion.
Show in the study text Report a problemFND-3268099602
03AnimalAnimal study (in vivo)Efficacy outcome
In rat hearts after ischemia-reperfusion, elamipretide alleviated the decrement in complex IV activity.
In plain wordsIn rats, elamipretide eased the drop in mitochondrial complex IV activity in heart fibers after ischemia-reperfusion.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseComplex IV activity after ischemia-reperfusion
Study
ratn: not reported in source
permeabilized ventricular fibers
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Respirometry with permeabilized ventricular fibers indicates that ischemia-reperfusion induced decrements in the activity of complexes I, II, and IV are alleviated with elamipretide.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we test the hypothesis that the cardiolipin-binding peptide elamipretide, a clinical-stage compound under investigation for diseases of mitochondrial dysfunction, mitigates impairments in mitochondrial structure-function observed after rat cardiac ischemia-reperfusion.
Show in the study text Report a problemFND-3268099603
04AnimalAnimal study (in vivo)Efficacy outcome
In rat hearts after ischemia-reperfusion, elamipretide improved disease-induced fragmentation of cristae networks.
In plain wordsIn rats, elamipretide reduced the breakup of the inner mitochondrial membrane folds in the heart after ischemia-reperfusion.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseFragmentation of cristae networks
Study
ratn: not reported in source
ischemia-reperfusion heart
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Serial block face scanning electron microscopy used to create 3D reconstructions of cristae ultrastructure reveals that disease-induced fragmentation of cristae networks are improved with elamipretide.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we test the hypothesis that the cardiolipin-binding peptide elamipretide, a clinical-stage compound under investigation for diseases of mitochondrial dysfunction, mitigates impairments in mitochondrial structure-function observed after rat cardiac ischemia-reperfusion.
Show in the study text Report a problemFND-3268099604
05AnimalAnimal study (in vivo)Efficacy outcome
In rat hearts after ischemia-reperfusion, elamipretide did not protect against the reduction of cardiolipin concentration.
In plain wordsIn rats, elamipretide did not prevent the fall in heart cardiolipin levels after ischemia-reperfusion.
Peptide
Elamipretide (SS-31)
Outcome
No significant changeCardiolipin concentration after ischemia-reperfusion
Study
ratn: not reported in source
ischemia-reperfusion heart
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Mass spectrometry shows elamipretide did not protect against the reduction of cardiolipin concentration after ischemia-reperfusion.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we test the hypothesis that the cardiolipin-binding peptide elamipretide, a clinical-stage compound under investigation for diseases of mitochondrial dysfunction, mitigates impairments in mitochondrial structure-function observed after rat cardiac ischemia-reperfusion.
Show in the study text Report a problemFND-3268099605
06LabIn vitro (cell-free)Mechanism
In biomimetic membranes, elamipretide improved biophysical properties by aggregating cardiolipin.
In plain wordsIn lab tests with model membranes, elamipretide improved membrane properties by clustering cardiolipin.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseBiophysical properties of biomimetic membranes
Study
n: not reported in source
biomimetic membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Finally, elamipretide improves biophysical properties of biomimetic membranes by aggregating cardiolipin.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we test the hypothesis that the cardiolipin-binding peptide elamipretide, a clinical-stage compound under investigation for diseases of mitochondrial dysfunction, mitigates impairments in mitochondrial structure-function observed after rat cardiac ischemia-reperfusion.
Show in the study text Report a problemFND-3268099606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.